CUMBERLAND PHARMACEUTICALS INC - 8-K Filing
Cumberland Pharmaceuticals shareholders approved a strategic transaction with Apotex on June 24, 2026. The proposal authorized the sale of Cumberland's FDA-approved commercial products and related assets under an April 22 Asset Purchase Agreement involving Nuvo Pharmaceuticals (Ireland) DAC, Apotex Inc., and Cumberland. Shareholders voting in favor represented approximately 70.03% of outstanding shares. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $CPIX